Valesta Clinical Research is categorized under Temporary Employment Contractors in Norwalk, CT .
Valesta Clinical Research was established in 0, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Temporary Employment Contractors business, which does work in the B2B market, and is classified as a Temporary Employment Contractors, under code number 5613200 by the NAICS.
If you are seeking more information, feel free to contact Mike Salvagno, Manager at the company’s branch by writing to 383 Main Avenue # 25, Norwalk, Connecticut CT 06851 or by phoning (203) 226-4243. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Valesta Clinical Research |
Contact Person: | Mike Salvagno, Manager |
Address: | 383 Main Avenue # 25, Norwalk, Connecticut 06851 |
Phone Number: | (203) 226-4243 |
Website Address: | onassignment.com |
Annual Revenue (USD): | $2.500.000 to $4.999.999 |
Location Type: | Branch |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Temporary Employment Contractors |
SIC Code: | 7363 |
NAICS Code: | 5613200 |
Share This Business: |
Valesta Clinical Research was started in 0 to provide professional Temporary Employment Contractors under the SIC code 7363 and NAICS code 5613200. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.
Feel free to contact Mike Salvagno, Manager for inquiries that concern Valesta Clinical Research by calling the company number (203) 226-4243, as your correspondence is most welcome. Additionally, the physical location of the branch of Valesta Clinical Research can be found at the coordinates 41.14067,-73.42594 as well as the street address 383 Main Avenue # 25 in Norwalk, Connecticut 06851.
For its online presence, you may visit Valesta Clinical Research’s website at onassignment.com and engage with its social media outlets through on Twitter and on Facebook.